Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
Outline of Final Research Achievements |
We recently showed that coronary spasm is induced in transgenic mice with enhanced phospholipase C-delta 1 activity (PLC-TG). Although calcium antagonist therapy is established as a treatment for coronary spastic angina, its precise mechanism remains unclear. In the present study, we investigated the efficacy of calcium antagonist and its mechanism using the PLC-TG mice. Calcium antagonist suppressed coronary spasm in the PLC-TG mice, as in the clinical cases. Alterations in protein expression levels and activity of calcium channels were suggested to be implicated in the pathogenesis of coronary spasm and in the therapeutic effect of calcium antagonist. Our study may help better understand calcium signaling in the coronary spasm and contribute to the development of novel therapy for drug-resistant coronary spasm.
|